{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T21:04:11Z","timestamp":1762981451059},"reference-count":14,"publisher":"Baishideng Publishing Group Inc.","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJH"],"published-print":{"date-parts":[[2022,8,27]]},"DOI":"10.4254\/wjh.v14.i8.1687","type":"journal-article","created":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T03:47:01Z","timestamp":1661485621000},"page":"1687-1691","source":"Crossref","is-referenced-by-count":2,"title":["Hemorrhagic colitis induced by trientine in a 51-year-old patient with Wilson\u2019s disease waiting for liver transplantation: A case report"],"prefix":"10.4254","volume":"14","author":[{"given":"Andreas","family":"Schult","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matts","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Asin-Cayuela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl Sigvard","family":"Olsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2060","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(00)00028-3"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v13.i6.634"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.11.007"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/dta.278"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-015-0031-z"},{"key":"B6","unstructured":"Dahlman T, Hartvig P, L\u00f6fholm M, Nordlinder H, L\u00f6\u00f6f L, Westermark K. Long-term treatment of Wilson\u2019s disease with triethylene tetramine dihydrochloride (trientine). QJM 1995; 88: 609-616"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awt035"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2010.01536.x"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2011.01711.x"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2008.01078.x"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22972"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2012.703240"},{"key":"B13","unstructured":"Efficacy and Safety of ALXN1840 (Formerly Named WTX101) Administered for 48 Weeks Versus Standard of Care in Patients With Wilson Disease With an Extension Period of up to 60 Months. [accessed 2022 Feb 25]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https:\/\/ClinicalTrials.gov\/show\/ ClinicalTrials.gov Identifier: NCT03403205"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(17)30293-5"}],"container-title":["World Journal of Hepatology"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/1948-5182\/full\/v14\/i8\/1687.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T03:47:57Z","timestamp":1661485677000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/1948-5182\/full\/v14\/i8\/1687.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,27]]},"references-count":14,"journal-issue":{"issue":"8"},"URL":"https:\/\/doi.org\/10.4254\/wjh.v14.i8.1687","relation":{},"ISSN":["1948-5182"],"issn-type":[{"value":"1948-5182","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,27]]}}}